Can I read BR J Haematol - 2026 - Breccia - Risk Factors and Reasons For Switching From Front Line Therapy in The Italian Chronic on EtoBox?

BR J Haematol - 2026 - Breccia - Risk Factors and Reasons For Switching From Front Line Therapy in The Italian Chronic by Mehmet Baysal is a document available to read on EtoBox.

What is BR J Haematol - 2026 - Breccia - Risk Factors and Reasons For Switching From Front Line Therapy in The Italian Chronic about?

This cohort study analyzed the risk factors for switching from first-line therapy in chronic myeloid leukaemia (CML) patients in Italy, focusing on the use of tyrosine kinase inhibitors. Out of 1662 patients, 29.6% required second-line therapy, primarily due to resistance or intolerance, with imatinib showing a higher risk of resistance compared to nilotinib and dasatinib. The study identified that younger patients and those with intermediate or high Eutos long-term survival risk were more likely to switch

Author

Mehmet Baysal

Language

EN